Shares of Prothena Corporation PLC (NASDAQ:PRTA) have been assigned a consensus recommendation of “Buy” from the fifteen analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $76.50.

Several brokerages recently weighed in on PRTA. Evercore ISI began coverage on shares of Prothena in a research report on Wednesday, August 16th. They set an “outperform” rating and a $83.00 price target for the company. Jefferies Group reissued a “buy” rating and set a $100.00 price target on shares of Prothena in a research report on Monday, October 2nd. Royal Bank Of Canada began coverage on shares of Prothena in a research report on Thursday, September 14th. They set an “outperform” rating and a $87.00 price target for the company. BTIG Research reduced their price target on shares of Prothena from $80.00 to $77.00 and set a “buy” rating for the company in a research report on Friday, September 29th. Finally, SunTrust Banks reissued a “buy” rating and set a $75.00 price target on shares of Prothena in a research report on Monday, October 2nd.

Shares of Prothena (NASDAQ:PRTA) traded up $0.83 on Friday, hitting $47.32. 356,655 shares of the company traded hands, compared to its average volume of 297,272. Prothena has a 12 month low of $44.03 and a 12 month high of $70.00.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.41) by $0.04. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. The firm’s quarterly revenue was down 33.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.26) earnings per share. research analysts forecast that Prothena will post -4.27 EPS for the current fiscal year.

In other Prothena news, Director Dennis J. Selkoe sold 3,500 shares of Prothena stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total value of $224,595.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher S. Henney sold 900 shares of Prothena stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $70.00, for a total transaction of $63,000.00. Following the completion of the sale, the director now directly owns 900 shares of the company’s stock, valued at approximately $63,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,424 shares of company stock valued at $1,922,787. 3.10% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the company. Bank of Montreal Can boosted its stake in shares of Prothena by 6.7% during the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 117 shares during the last quarter. Quantbot Technologies LP boosted its stake in shares of Prothena by 672.7% during the 2nd quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,628 shares during the last quarter. Strs Ohio boosted its stake in shares of Prothena by 69.2% during the 3rd quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 900 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Prothena by 187.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 1,549 shares during the last quarter. Finally, Fieldpoint Private Securities LLC purchased a new position in shares of Prothena during the 3rd quarter worth $162,000.

WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/02/prothena-corporation-plc-prta-given-average-rating-of-buy-by-brokerages.html.

Prothena Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Stock Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related stocks with our FREE daily email newsletter.